Fresenius SE & Co. KGaA's Fresenius Helios and Fresenius Kabi segments drive net sales growth.

Fitch Ratings has affirmed Fresenius SE & Co. KGaA's rating, citing the company's profitability prospects following its restructuring. Fresenius specializes in medical drugs, equipment, and devices for clinical hospitalization and home use. Its net sales are primarily driven by hospital administration and engineering (59.2%), and perfusion and clinical nutrition (39.1%).

Fitch Ratings has affirmed Fresenius SE & Co. KGaA's rating, citing the company's improved profitability prospects following its restructuring. The German healthcare company specializes in medical drugs, equipment, and devices for clinical hospitalization and home use, with net sales primarily driven by hospital administration and engineering (59.2%) and perfusion and clinical nutrition (39.1%) [1].

Fresenius Medical Care AG (FMS) announced a share buyback program on Monday, launching the first tranche valued at up to EUR 600 million, scheduled for completion by April 30, 2026. The buyback is part of the company's new capital allocation framework, supporting its FME Reignite strategy [2].

The share buyback program comes amidst positive market sentiment. Fresenius Medical Care's stock price has been trading favorably, with a 0.39% increase at EUR 41.31 on the XETRA as of July 2, 2025. The company's stock is also trading at $24.05 on the New York Stock Exchange, up 0.15% from pre-market trading [2].

Fitch Ratings' affirmation of Fresenius' rating highlights the company's strategic focus on profitability and market positioning. The share buyback program and the restructuring efforts reflect a commitment to shareholder value and financial health. As Fresenius continues to navigate the healthcare landscape, investors will closely monitor these developments for further insights into the company's financial performance and growth prospects.

References:
[1] https://www.inkl.com/news/amphastar-secures-fda-nod-for-iron-sucrose-injection-analysts-eye-major-sales-momentum
[2] https://www.nasdaq.com/articles/fresenius-medical-launches-eur-600-mln-first-tranche-eur-1-bln-share-buyback